Urovant Sciences® Named One of 2022 “Best Places to Work” in Orange County
Urovant Sciences has been recognized as one of the Best Places to Work for the second consecutive year by the Orange County Business Journal. This accolade, based on employee feedback, highlights the company's people-focused culture and commitment to enhancing urologic care. Additionally, Urovant received the Great Place to Work certification in 2022, further underscoring its workplace excellence. Urovant’s CEO, James Robinson, expressed pride in these recognitions, emphasizing the company's values of integrity and innovation.
- Recognized as one of the Best Places to Work by Orange County Business Journal for the second consecutive year.
- Received Great Place to Work certification in 2022, indicating high employee satisfaction.
- Highlights a strong company culture focused on integrity and innovation.
- None.
-
This is Urovant’s second year in a row to earn this recognition by
Orange County Business Journal -
Urovant has also received a 2022 global
Great Place to Work™ certification. -
The culmination of these two awards reflects the company’s people focused culture and underscores the opinion of employees, dedicated to improving urologic care for patients in
the United States and beyond.
“It’s an honor to be recognized as a Best Place to Work not once, but twice by the
The awards program was created in 2009 and is a project of the
The recognition by the OCBJ follows on a separate recognition Urovant Sciences received in 2022, the
About Urovant Sciences
Urovant Sciences is a biopharmaceutical company focused on developing and commercializing innovative therapies for areas of unmet need, with a dedicated focus in Urology. The Company’s lead product, GEMTESA® (vibegron), is an oral, once-daily (75 mg) small molecule beta-3 agonist for the treatment of adult patients with overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and urinary frequency. GEMTESA was approved by the
About Sumitovant Biopharma
Sumitovant is a technology-driven biopharmaceutical company accelerating development of new potential therapies for patients with high unmet medical need. Through our subsidiary portfolio and use of embedded computational technology platforms to generate business and scientific insights, Sumitovant has supported development of FDA-approved products and advanced a promising pipeline of early-through late-stage investigational assets for other serious conditions. Sumitovant’s subsidiary portfolio includes wholly-owned Enzyvant, Urovant, Spirovant and Altavant, and majority-owned
About the 2022 Best Places to Work in
Organizations from across the county entered the two-part process to determine the Best Places to Work in
About
About GEMTESA®
GEMTESA is a prescription medicine for adults used to treat the following symptoms due to a condition called overactive bladder:
- urge urinary incontinence: a strong need to urinate with leaking or wetting accidents
- urgency: the need to urinate right away
- frequency: urinating often
It is not known if GEMTESA is safe and effective in children.
IMPORTANT SAFETY INFORMATION
Do not take GEMTESA if you are allergic to vibegron or any of the ingredients in GEMTESA.
Before you take GEMTESA, tell your doctor about all your medical conditions, including if you have liver problems; have kidney problems; have trouble emptying your bladder or you have a weak urine stream; take medicines that contain digoxin; are pregnant or plan to become pregnant (it is not known if GEMTESA will harm your unborn baby; talk to your doctor if you are pregnant or plan to become pregnant); are breastfeeding or plan to breastfeed (it is not known if GEMTESA passes into your breast milk; talk to your doctor about the best way to feed your baby if you take GEMTESA).
Tell your doctor about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Know the medicines you take. Keep a list of them to show your doctor and pharmacist when you get a new medicine.
What are the possible side effects of GEMTESA?
GEMTESA may cause serious side effects including the inability to empty your bladder (urinary retention). GEMTESA may increase your chances of not being able to empty your bladder, especially if you have bladder outlet obstruction or take other medicines for treatment of overactive bladder. Tell your doctor right away if you are unable to empty your bladder. The most common side effects of GEMTESA include headache, urinary tract infection, nasal congestion, sore throat or runny nose, diarrhea, nausea, and upper respiratory tract infection. These are not all the possible side effects of GEMTESA. For more information, ask your doctor or pharmacist.
Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
Please click here for full Product Information for GEMTESA.
UROVANT, UROVANT SCIENCES, GEMTESA and the UROVANT SCIENCES logo are trademarks of
View source version on businesswire.com: https://www.businesswire.com/news/home/20220707005431/en/
Urovant Sciences
Vice President, Corporate Communications
949-436-3116
alana.darden@Urovant.com
media@urovant.com
Sumitovant Biopharma
VP, Head of Corporate Communications
media@sumitovant.com
Source:
FAQ
What recognition did Urovant Sciences receive in 2022?
Who is the CEO of Urovant Sciences?
What does the Great Place to Work certification signify?